Related Experiment Video
Updated: Jun 1, 2026
08:04
Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
SNPs in genes encoding G proteins in pharmacogenetics
Stefanie Klenke1, Winfried Siffert
1Institut für Pharmakogenetik, Universität Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany. stefanie.klenke@uk-essen.de
Pharmacogenomics
|May 31, 2011
Summary
Genetic variations in G-protein signaling pathways, specifically in GNB3, GNAS, and GNAQ genes, are linked to complex diseases. These G-protein polymorphisms offer potential for personalized medicine by predicting drug response and side effects.
Area of Science:
- Molecular Biology
- Pharmacogenetics
- Genetics
Background:
- Heterotrimeric guanine-binding proteins (G proteins) mediate cell surface signal transduction.
- G proteins are crucial in numerous physiological and pathophysiological processes.
- Polymorphisms in GNB3, GNAS, and GNAQ genes are key areas of research.
Purpose of the Study:
- To investigate the association between G-protein gene polymorphisms and complex phenotypes.
- To explore the utility of G-protein polymorphisms in pharmacogenetic studies.
- To determine if G-protein variations can guide individualized drug treatment.
Main Methods:
- Focus on polymorphisms in GNB3, GNAS, and GNAQ genes.
- Analysis of G-protein signaling alterations and their link to complex phenotypes.
- Review of existing pharmacogenetic studies on G-protein polymorphisms.
Main Results:
- G-protein gene polymorphisms are associated with diverse complex phenotypes.
- Alterations in G-protein signaling can contribute to multiple disorders.
- Pharmacogenetic studies show links between G-protein polymorphisms and drug response/adverse effects.
Conclusions:
- G-protein polymorphisms are implicated in various diseases.
- G proteins serve as a convergence point for receptor-effector signaling.
- G-protein gene variations may enable personalized pharmacotherapy for improved efficacy and safety.
Related Concept Videos
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...